Markets & Investing
Why Alts.Co Invested in the Psychedelics Industry (LIVE EVENT)
Nucleus CEO, Logan Lenz, sits down with Stefan von Imhof, the CEO of Alts.co to discuss Nucleus and the massive opportunity for the psychedelics industry…
Nucleus CEO, Logan Lenz, sits down with Stefan von Imhof, the CEO of Alts.co to discuss Nucleus and the massive opportunity for the psychedelics industry in the coming years.
A few months back, Alts published a deep dive on Nucleus, a venture studio for psychedelics (and Psychedelic Invest’s parent company).
Stefan is the co-founder and CEO of Alts.co. He’s a huge fan of alternative investing and has a strong background in alternative asset analysis and valuations. Prior to co-founding Alts.co, Stefan was Head of Product at Flippa where he created Flippa’s Due Diligence Program, He also spent time at Citrix and lynda.com, which was bought by LinkedIn, and was the first product manager at HG Insights, a market intelligence company that sold to Riverwood Capital Partners in 2020. Originally from Boston and later Santa Barbara, CA, he now lives in Australia with his wife & Boston Terrier, Charlie.
More About Alts.co
Alts.co provides original research and insights you can trust on alternative assets. Over 85,000 subscribers are delivered investment opportunities and insights straight to their inbox.
Investing in Nucleus
For those who don’t know by now, Nucleus currently allows anyone to invest in the company with as little as $200. All you must do is visit the Wefunder page, select your investment amount, and go through Wefunder’s transaction process.
Stay tuned for more Nucleus events and webinars as the campaign continues.
RSVP To Reserve Your Spot
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment